In focus · trending topic

Phase 2b clinical trial

10 stories · following the connections

Mallinckrodt to Acquire Ocera Therapeutics and OCR-002, its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy

By Nasdaq OMXNov 2, 2017, 10:56 AM UTC

Ocera to Present at the 16th Annual Needham Healthcare Conference

By Nasdaq OMXMar 27, 2017, 8:05 PM UTC

Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy

By Nasdaq OMXJan 30, 2017, 12:00 PM UTC

Ocera to Present at the Stifel 2016 Healthcare Conference

By Nasdaq OMXNov 9, 2016, 2:05 PM UTC

Ocera Therapeutics Reports Third Quarter 2016 Financial Results and Company Update

By Nasdaq OMXNov 2, 2016, 1:05 PM UTC

Ocera Therapeutics Appoints Biopharmaceutical Veteran Willard Dere, M.D. to Board of Directors

By Nasdaq OMXOct 28, 2016, 1:05 PM UTC

Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure

By Nasdaq OMXSep 21, 2016, 8:05 PM UTC

Ocera to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference

By Nasdaq OMXSep 20, 2016, 1:10 PM UTC